Skip to main content

Table 3 Analysis of efficacy (N = 89)

From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Endpoint

 

95% CI

Response rate

10.1%

4.7-18.3%

Disease control rate

65.2%

54.3-75.0%

TTF

4.1 months

2.8-4.8 months

PFS

5.4 months

4.1-6.2 months

OS

14.5 months

11.8-17.0 months

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us